The SWIFT-1 and SWIFT-2 trials, published in The New England Journal of Medicine in 2024, investigated the efficacy of depemokimab in patients with severe uncontrolled asthma and an eosinophilic phenotype. Key Findings: Conclusion: Depemokimab significantly reduced the annualized rate of … Read More
